SEC For	m 4																		
	FORM	4	UNITE	O STA	TES	s se			ES AND		ANG	EC	OMMI	SSION		OMB	APPROV	/AL	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					d purs	suant t	o Sectior	n 16(a	a) of the Secu	urities Exch	ange Ad	ct of 19	_	HIP	Estim	Numbe ated av	verage burden	0.5	
1. Name and Address of Reporting Person [*] Burstein Jennifer					2.1	or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc.								5. Relationship of Reporting Person(s) to Issu (Check all applicable) X Director 10% Ow					
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2020									Officer (give title Other (specify below) below)					
45 WIGGINS AVENUE (Street) BEDFORD MA 01730					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S		(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action	ction 2A. Deemed Execution Date,			Code (Instr. 5)			d (A) or) or 5. Amount of		Form Iy (D) o	n: Direct or Indirect I nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code V	/ Amou	nt	(A) or (D)	Price	Transaction				Instr. 4)	
		-							uired, Dis s, options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date, T	ate, Transa Code (I				6. Date Exer Expiration D (Month/Day/	of S Und Deri	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiratio Date	n Title	e	Amount or Number of Shares						
Director Stock Option (Right to Buy)	\$26.53	06/03/2020			A		14,777		(1)	06/02/203		nmon œck	14,777	\$0.00	14,77	7	D		

Explanation of Responses:

1. The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

/s/ Stephen Tulipano	, <u>Attorney-</u>	06/05/2020
in-Fact		00/05/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.